After 26 weeks of follow-up, the two higher drug doses elicited a mean 12.1% weight reduction from baseline, whereas those on placebo lost 2.3% of their body weight
This initiates the complex process of blood sugar regulation and altered gastric emptying
When asked about the results of the study, Amber Alhadeff , a neuroscientist from the Monell Chemical Senses Center, stated that she believes they open a door in terms of GLP-1 possibilities
Phase 2 trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) reported mean weight reductions of up to approximately 24% over 48 weeks in adults with obesity notably higher than results seen with currently approved agents
As the discontinuation rates were also high with the twice daily danuglipron at the phase 2 obesity trial (as discussed above), twice daily danuglirpon formulation will not advance into phase 3 studies, but an improved once-daily formulation with an aim to improve tolerability profile is currently under assessment [27]
Scale-Related Wins Are Only Part of the Story Its all too easy to get caught up in the weight loss wins that show up on the scale and overlook the ones that dont
